HCW Biologics is trading at $1.23, up 6.03%, with biotech-sector gains offering possible support, though the catalyst remains uncertain. - No new company-specific announcement was identified for October 22; the latest release, on October 9, described FDA guidance and IND preparation targeted for the first half of 2027. - Biotech ETF XBI was up 3.64% pre-market, while broad-market futures were sharply lower. - No reliable pre-market volume figure was provided.